Method for treating infectious diseases with isothiocyanate functional compounds

Patent metadata

Field	Value
Publication number	US-10864187-B2
Application number	US-201916453972-A
Country	US
Kind code	B2
Filing date	Jun 26, 2019
Priority date	Jul 26, 2012
Publication date	Dec 15, 2020
Grant date	Dec 15, 2020

Abstract

A method for treating an infectious disease, including the step of administering an isothiocyanate functional surfactant to a patient having an infectious disease. In one embodiment, the protonated form of the isothiocyanate functional surfactant is represented by the following chemical structure:

First claim

What is claimed and desired to be secured by Letters Patent of the United States is:

1. A method for treating a bacterial infection, comprising the step of:
administering an isothiocyanate functional surfactant to a patient having a bacterial infection, wherein the isothiocyanate functional surfactant is represented by the following chemical structure:

wherein R 1 is selected from the group consisting of an alkyl group containing 1 to 25 carbon atom(s); wherein R 2 is selected from the group consisting of NCS; and wherein R 3 -R 5 are each independently selected from the group consisting of H; OH; and an alkyl, and alkanoyl group containing 1 to 25 carbon atom(s) with the proviso that at least one of R 3 -R 5 is selected from the group consisting of an alkyl, and alkanoyl, group containing 8 to 25 carbon atoms.

2. The method according to claim 1 , wherein the protonated form of the isothiocyanate functional surfactant is represented by the following chemical structure:

wherein X comprises an integer ranging from approximately 1 to approximately 25, and wherein Y comprises an integer ranging from approximately 6 to approximately 25.

3. The method according to claim 1 , wherein the protonated form of the isothiocyanate functional surfactant is represented by the following chemical structure:

4. The method according to claim 1 , wherein the deprotonated form of the isothiocyanate functional surfactant is represented by the following chemical structure:

wherein R 1 is selected from the group consisting of an alkyl group containing 1 to 25 carbon atom(s); wherein R 2 is selected from the group consisting of NCS; and wherein R 3 -R 5 are each independently selected from the group consisting of H; OH; and an alkyl, and alkanoyl group containing 1 to 25 carbon atom(s) with the proviso that at least one of R 3 -R 5 is selected from the group consisting of an alkyl, and alkanoyl, group containing 8 to 25 carbon atoms; and wherein X comprises a counter cation.

5. The method according to claim 1 , wherein the patient is a mammal.

6. The method according to claim 1 , wherein the mammal is a human.

7. A method for treating a viral infection, comprising the step of:
administering an isothiocyanate functional surfactant to a patient having a viral infection, wherein the isothiocyanate functional surfactant is represented by the following chemical structure:

wherein R 1 is selected from the group consisting of an alkyl group containing 1 to 25 carbon atom(s); wherein R 2 is selected from the group consisting of NCS; and wherein R 3 -R 5 are each independently selected from the group consisting of H; OH; and an alkyl, and alkanoyl group containing 1 to 25 carbon atom(s) with the proviso that at least one of R 3 -R 5 is selected from the group consisting of an alkyl, and alkanoyl, group containing 8 to 25 carbon atoms.

8. The method according to claim 7 , wherein the protonated form of the isothiocyanate functional surfactant is represented by the following chemical structure:

wherein X comprises an integer ranging from approximately 1 to approximately 25, and wherein Y comprises an integer ranging from approximately 6 to approximately 25.

9. The method according to claim 7 , wherein the protonated form of the isothiocyanate functional surfactant is represented by the following chemical structure:

10. The method according to claim 7 , wherein the deprotonated form of the isothiocyanate functional surfactant is represented by the following chemical structure:

wherein R 1 is selected from the group consisting of an alkyl group containing 1 to 25 carbon atom(s); wherein R 2 is selected from the group consisting of NCS; and wherein R 3 -R 5 are each independently selected from the group consisting of H; OH; and an alkyl, and alkanoyl group containing 1 to 25 carbon atom(s) with the proviso that at least one of R 3 -R 5 is selected from the group consisting of an alkyl, and alkanoyl, group containing 8 to 25 carbon atoms; and wherein X comprises a counter cation.

11. The method according to claim 7 , wherein the patient is a mammal.

12. The method according to claim 7 , wherein the mammal is a human.

13. A method for treating a fungal infection, comprising the step of:
administering an isothiocyanate functional surfactant to a patient having a fungal infection, wherein the isothiocyanate functional surfactant is represented by the following chemical structure:

wherein R 1 is selected from the group consisting of an alkyl group containing 1 to 25 carbon atom(s); wherein R 2 is selected from the group consisting of NCS; and wherein R 3 -R 5 are each independently selected from the group consisting of H; OH; and an alkyl, and alkanoyl group containing 1 to 25 carbon atom(s) with the proviso that at least one of R 3 -R 5 is selected from the group consisting of an alkyl, and alkanoyl, group containing 8 to 25 carbon atoms.

14. The method according to claim 13 , wherein the protonated form of the isothiocyanate functional surfactant is represented by the following chemical structure:

wherein X comprises an integer ranging from approximately 1 to approximately 25, and wherein Y comprises an integer ranging from approximately 6 to approximately 25.

15. The method according to claim 13 , wherein the protonated form of the isothiocyanate functional surfactant is represented by the following chemical structure:

16. The method according to claim 13 , wherein the deprotonated form of the isothiocyanate functional surfactant is represented by the following chemical structure:

wherein R 1 is selected from the group consisting of an alkyl group containing 1 to 25 carbon atom(s); wherein R 2 is selected from the group consisting of NCS; and wherein R 3 -R 5 are each independently selected from the group consisting of H; OH; and an alkyl, and alkanoyl group containing 1 to 25 carbon atom(s) with the proviso that at least one of R 3 -R 5 is selected from the group consisting of an alkyl, and alkanoyl, group containing 8 to 25 carbon atoms; and wherein X comprises a counter cation.

17. The method according to claim 13 , wherein the patient is a mammal.

18. The method according to claim 13 , wherein the mammal is a human.

Assignees

• Silver Michael E
• The William M Yarbrough Found

Inventors

• Silver Michael E

Classifications

• Y02A50/30

  Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change · CPC title

• A61K31/26 Primary

  Cyanate or isocyanate esters; Thiocyanate or isothiocyanate esters · CPC title

• A61K31/16

  Amides, e.g. hydroxamic acids · CPC title

• A61K9/0014

  Skin, i.e. galenical aspects of topical compositions (non-active ingredients are additionally classified in A61K47/00; A61K9/0009, A61K9/0021, A61K9/7015, A61K9/7023 take precedence; cosmetic preparations A61K8/00, A61Q; preparations for wound dressings or bandages A61L26/00) · CPC title

• A61K31/195

  having an amino group · CPC title